Literature DB >> 24813058

Values and preferences for oral antithrombotic therapy in patients with atrial fibrillation: physician and patient perspectives.

Pablo Alonso-Coello1, Victor M Montori2, M Gloria Díaz3, Philip J Devereaux4, Gemma Mas1, Ana I Diez5, Ivan Solà1, Mercè Roura6, Juan C Souto7, Sven Oliver8, Rafael Ruiz9, Blanca Coll-Vinent10, Ignasi Gich1, Holger J Schünemann4, Gordon Guyatt4.   

Abstract

BACKGROUND: Exploration of values and preferences in the context of anticoagulation therapy for atrial fibrillation (AF) remains limited. To better characterize the distribution of patient and physician values and preferences relevant to decisions regarding anticoagulation in patients with AF, we conducted interviews with patients at risk of developing AF and physicians who manage patients with AF.
METHODS: We interviewed 96 outpatients and 96 physicians in a multicenter study and elicited the maximal increased risk of bleeding (threshold risk) that respondents would tolerate with warfarin vs. aspirin to achieve a reduction in three strokes in 100 patients over a 2-year period. We used the probabilistic version of the threshold technique.
RESULTS: The median threshold risk for both patients and physicians was 10 additional bleeds (10 P = 0.7). In both groups, we observed large variability in the threshold number of bleeds, with wider variability in patients than clinicians [patient range: 0-100, physician range: 0-50]. We observed one cluster of patients and physicians who would tolerate <10 bleeds and another cluster of patients, but not physicians, who would accept more than 35.
CONCLUSIONS: Our findings suggest wide variability in patient and physician values and preferences regarding the trade-off between strokes and bleeds. Results suggest that in individual decision making, physician and patient values and preferences will often be discordant; this mandates tailoring treatment to the individual patient's preferences.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  anticoagulation; antithrombotic treatment; decision making; preferences; values

Mesh:

Substances:

Year:  2014        PMID: 24813058      PMCID: PMC5810657          DOI: 10.1111/hex.12201

Source DB:  PubMed          Journal:  Health Expect        ISSN: 1369-6513            Impact factor:   3.377


  33 in total

1.  ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology.

Authors:  V Fuster; L E Rydén; R W Asinger; D S Cannom; H J Crijns; R L Frye; J L Halperin; G N Kay; W W Klein; S Lévy; R L McNamara; E N Prystowsky; L S Wann; D G Wyse
Journal:  Eur Heart J       Date:  2001-10       Impact factor: 29.983

2.  Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study.

Authors:  P J Devereaux; D R Anderson; M J Gardner; W Putnam; G J Flowerdew; B F Brownell; S Nagpal; J L Cox
Journal:  BMJ       Date:  2001-11-24

3.  Is warfarin really underused in patients with atrial fibrillation?

Authors:  S D Weisbord; J Whittle; R C Brooks
Journal:  J Gen Intern Med       Date:  2001-11       Impact factor: 5.128

4.  Patient preference-based treatment thresholds and recommendations: a comparison of decision-analytic modeling with the probability-tradeoff technique.

Authors:  M Man-Son-Hing; A Laupacis; A M O'Connor; D Coyle; R Berquist; F McAlister
Journal:  Med Decis Making       Date:  2000 Oct-Dec       Impact factor: 2.583

5.  Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis.

Authors:  Carl van Walraven; Robert G Hart; Daniel E Singer; Andreas Laupacis; Stuart Connolly; Palle Petersen; Peter J Koudstaal; Yuchiao Chang; Beppie Hellemons
Journal:  JAMA       Date:  2002-11-20       Impact factor: 56.272

6.  Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.

Authors:  Robert G Hart; Lesly A Pearce; Maria I Aguilar
Journal:  Ann Intern Med       Date:  2007-06-19       Impact factor: 25.391

Review 7.  Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data.

Authors:  Michael Hughes; Gregory Y H Lip
Journal:  Thromb Haemost       Date:  2008-02       Impact factor: 5.249

8.  Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates.

Authors:  W B Kannel; P A Wolf; E J Benjamin; D Levy
Journal:  Am J Cardiol       Date:  1998-10-16       Impact factor: 2.778

9.  A patient decision aid to support shared decision-making on anti-thrombotic treatment of patients with atrial fibrillation: randomised controlled trial.

Authors:  Richard G Thomson; Martin P Eccles; I Nick Steen; Jane Greenaway; Lynne Stobbart; Madeleine J Murtagh; Carl R May
Journal:  Qual Saf Health Care       Date:  2007-06

10.  Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications.

Authors:  W M Feinberg; J L Blackshear; A Laupacis; R Kronmal; R G Hart
Journal:  Arch Intern Med       Date:  1995-03-13
View more
  15 in total

1. 

Authors:  Theodore Wein; M Patrice Lindsay; David J Gladstone; Alexandre Poppe; Alan Bell; Leanne K Casaubon; Norine Foley; Shelagh B Coutts; Jafna Cox; James Douketis; Thalia Field; Laura Gioia; Jeffrey Habert; Eddy Lang; Shamir R Mehta; Christine Papoushek; William Semchuk; Mikul Sharma; Jacob A Udell; Stephanie Lawrence; Anita Mountain; Gord Gubitz; Dar Dowlatshahi; Anne Simard; Andrea de Jong; Eric E Smith
Journal:  CMAJ       Date:  2020-10-05       Impact factor: 8.262

2.  Canadian Stroke Best Practice Recommendations, seventh edition: acetylsalicylic acid for prevention of vascular events.

Authors:  Theodore Wein; M Patrice Lindsay; David J Gladstone; Alexandre Poppe; Alan Bell; Leanne K Casaubon; Norine Foley; Shelagh B Coutts; Jafna Cox; James Douketis; Thalia Field; Laura Gioia; Jeffrey Habert; Eddy Lang; Shamir R Mehta; Christine Papoushek; William Semchuk; Mikul Sharma; Jacob A Udell; Stephanie Lawrence; Anita Mountain; Gord Gubitz; Dar Dowlatshahi; Anne Simard; Andrea de Jong; Eric E Smith
Journal:  CMAJ       Date:  2020-03-23       Impact factor: 8.262

Review 3.  Management of Antiplatelet and Anticoagulant Agents before and after Polypectomy.

Authors:  Jennifer J Telford; Neena S Abraham
Journal:  Gastrointest Endosc Clin N Am       Date:  2022-04

Review 4.  Developing a Conversation Aid to Support Shared Decision Making: Reflections on Designing Anticoagulation Choice.

Authors:  Claudia L Zeballos-Palacios; Ian G Hargraves; Peter A Noseworthy; Megan E Branda; Marleen Kunneman; Bruce Burnett; Michael R Gionfriddo; Christopher J McLeod; Haeshik Gorr; Juan Pablo Brito; Victor M Montori
Journal:  Mayo Clin Proc       Date:  2019-01-11       Impact factor: 7.616

5.  Treatment Preferences in Germany Differ Among Apheresis Patients with Severe Hypercholesterolemia.

Authors:  Axel C Mühlbacher; Andrew Sadler; Franz-Werner Dippel; Christin Juhnke
Journal:  Pharmacoeconomics       Date:  2018-04       Impact factor: 4.981

6.  What are the Relevant Outcomes of the Periodic Health Examination? A Comparison of Citizens' and Experts' Ratings.

Authors:  Isolde Sommer; Viktoria Titscher; Monika Szelag; Gerald Gartlehner
Journal:  Patient Prefer Adherence       Date:  2021-01-18       Impact factor: 2.711

7.  Electronic physician notifications to improve guideline-based anticoagulation in atrial fibrillation: a randomized controlled trial.

Authors:  Jeffrey M Ashburner; Steven J Atlas; Shaan Khurshid; Lu-Chen Weng; Olivia L Hulme; Yuchiao Chang; Daniel E Singer; Patrick T Ellinor; Steven A Lubitz
Journal:  J Gen Intern Med       Date:  2018-08-03       Impact factor: 6.473

8.  Cost-effectiveness analysis of dabigatran and anticoagulation monitoring strategies of vitamin K antagonist.

Authors:  Misericòrdia Carles; Max Brosa; Juan Carlos Souto; Josep Maria Garcia-Alamino; Gordon Guyatt; Pablo Alonso-Coello
Journal:  BMC Health Serv Res       Date:  2015-07-28       Impact factor: 2.655

9.  Patient values and preferences on transcatheter or surgical aortic valve replacement therapy for aortic stenosis: a systematic review.

Authors:  Lyubov Lytvyn; Gordon H Guyatt; Veena Manja; Reed A Siemieniuk; Yuan Zhang; Thomas Agoritsas; Per O Vandvik
Journal:  BMJ Open       Date:  2016-09-29       Impact factor: 2.692

Review 10.  Patient Preferences for Oral Anticoagulation Therapy in Atrial Fibrillation: A Systematic Literature Review.

Authors:  Thomas Wilke; Sabine Bauer; Sabrina Mueller; Thomas Kohlmann; Rupert Bauersachs
Journal:  Patient       Date:  2017-02       Impact factor: 3.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.